| Outcome Measures: |
Primary: Change From Baseline in Hemoglobin A1c (HbA1c), HbA1c is measured to identify average plasma glucose concentration over prolonged periods of time, Baseline to Week 24 | Secondary: Change From Baseline in Hemoglobin A1c (HbA1c) in Week 12, HbA1c is measured to identify average plasma glucose concentration over prolonged periods of time, Baseline to Week12|Percentage of Participant Who Achieved HbA1c<7% and ≤6.5%, the ratio of participant Who Achieved HbA1c\<7% and ≤6.5%, Baseline to Week24|Percentage of Participant Who Achieved HbA1c<7% and ≤6.5% without Hypoglycaemic Episodes, The ratio of participant Who Achieved HbA1c\<7% and ≤6.5% without Hypoglycaemic Episodes, Baseline to Week24|Change From Baseline in Fasting Plasma Glucose(FPG), the plasma glucose concentration on an empty stomach, Baseline to Week12|Change From Baseline in Fasting Plasma Glucose(FPG) in Week24, the plasma glucose concentration on an empty stomach, Baseline to Week24|Change From Baseline in 7-Point Self-Monitoring Blood Glucose (SMBG) Values, SMBG 7-point profiles were measured at fasting, 2-hour post morning meal, pre midday meal, 2-hour post midday meal, pre evening meal, 2-hours post evening meal, and bedtime., Baseline to Week12|Change From Baseline in 7-Point Self-Monitoring Blood Glucose (SMBG) Values in Week24, SMBG 7-point profiles were measured at fasting, 2-hour post morning meal, pre midday meal, 2-hour post midday meal, pre evening meal, 2-hours post evening meal, and bedtime., Baseline to Week24|Change From Baseline in Body weight, Change in body weight, Baseline to Week24|Number of Treatment-emergent Adverse Events (TEAE) and Serious Adverse Events(SAE), Safety, from baseline to Week25
|
